Similar to B-ALL Nalm-6 cell line, CCND1and BCL9 overexpression as a post-translationalphenomenon following the reduced expression of miR15b,miR-424, and miR-101 in MVs may be useful as apotential therapeutic target in ALL patients. The gene discussed is BCL9; the disease is acute lymphoblastic leukemia.